Lagerstandorte

New Jersey, USA
Czech Republic, EU
Mumbai, India

* Vorbehaltlich Verfügbarkeit

Dokumentation

MSDS herunterladen

Beispiel-COA herunterladen

Enthält: HPLC, MASS/LC-MS, 1H-NMR, FT-IR, Gehalt, Structure Elucidation Report (SER) sowie zusätzliche analytische Daten je nach Produkt.

911417-62-42-(3-(4-((1H-Indazol-5-yl)amino)quinazolin-2-yl)phenoxy)acetic Acid

● Auf Lager

Katalog-Nr.::	VE0025752
CAS-Nr.::	911417-62-4
Summenformel::	C23H17N5O3
Molare Masse::	411.42 g/mol

Angebot anfordern

Zur RFQ-Liste hinzufügen

Zusätzliche Informationen zu CAS 911417-62-4

Parent drug

Belumosudil

IUPAC-Name

2-[3-[4-[(1H-Indazol-5-yl)amino]quinazolin-2-yl]phenoxy]acetic Acid

Synonyme

Acetic acid, 2-[3-[4-(1H-indazol-5-ylamino)-2-quinazolinyl]phenoxy]-;

SMILES

O=C(O)COC1=CC=CC(C2=NC(NC3=CC4=C(NN=C4)C=C3)=C5C=CC=CC5=N2)=C1

InChI

InChI=1S/C23H17N5O3/c29-21(30)13-31-17-5-3-4-14(11-17)22-26-20-7-2-1-6-18(20)23(27-22)25-16-8-9-19-15(10-16)12-24-28-19/h1-12H,13H2,(H,24,28)(H,29,30)(H,25,26,27)

Beschreibung

2-(3-(4-((1H-Indazol-5-yl)amino)quinazolin-2-yl)phenoxy)acetic acid (CAS 911417-62-4) is a structurally related process impurity characterized by a quinazolinyl core linked to an indazolyl amine and a terminal carboxylic acid. Its polyaromatic heterocyclic framework produces strong UV chromophores and moderate lipophilicity while the acetic acid moiety confers acidic ionization that alters retention in reversed-phase LC and HPLC. Typical identification and quantification employ LC-UV, LC-MS and 1H/13C NMR with diagnostic mass fragments from the indazole and quinazoline subunits. Routine monitoring is advised because this impurity can affect API purity, stability and formulation performance.